Back to User profile » Dr Jodi I Luchs
Papers published by Dr Jodi I Luchs:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
Schechter BA, Urbieta M, Bacharach J, Toyos M, Smyth-Medina R, Mitchell B, Luchs JI
Clinical Ophthalmology 2022, 16:4145-4151
Published Date: 13 December 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P
Clinical Ophthalmology 2021, 15:129-140
Published Date: 12 January 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J
Clinical Ophthalmology 2020, 14:119-126
Published Date: 14 January 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
Yeu E, Goldberg DF, Mah FS, Beckman KA, Luchs JI, Solomon JD, White DE, Gupta PK
Clinical Ophthalmology 2019, 13:887-894
Published Date: 27 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2019, 13:215-216
Published Date: 24 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:2637-2638
Published Date: 14 December 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:1921-1929
Published Date: 2 October 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Making the diagnosis of Sjögren’s syndrome in patients with dry eye
Beckman KA, Luchs J, Milner MS
Clinical Ophthalmology 2016, 10:43-53
Published Date: 24 December 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Azithromycin in DuraSite® for the treatment of blepharitis
Jodi Luchs
Clinical Ophthalmology 2010, 4:681-688
Published Date: 28 June 2010